Portal de Periódicos da CAPES

Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii

2022; American Society for Microbiology; Volume: 10; Issue: 5 Linguagem: Inglês

10.1128/spectrum.00479-22

2165-0497

Sara Alosaimy, Taylor Morrisette, Abdalhamid M Lagnf, Leonor M. Rojas, Madeline King, Benjamin Pullinger, Athena L V Hobbs, Nicholson B. Perkins, Michael P. Veve, Jeannette Bouchard, Tristan Gore, Bruce M Jones, James Truong, Justin Andrade, Glen Huang, Reese Cosimi, S. Lena Kang‐Birken, Kyle C. Molina, Mark Biagi, Michael Pierce, Marco R. Scipione, Jing Zhao, Susan L. Davis, Michael J. Rybak,

Antibiotic Use and Resistance

Forty-six patients were treated with eravacycline (ERV) for Acinetobacter baumannii infections, where 69.5% of isolates were carbapenem resistant (CRAB). Infections were primarily pulmonary (58.3%), and most patients received combination therapy (84.4%). The median (IQR) ERV duration was 6.9 days (5.1 to 11.1). Thirty-day mortality was 23.9% in the cohort and 21.9% in CRAB patients. One patient experienced an ERV-possible adverse event.